3PGDH Antibody (6B2): sc-100317

3PGDH Antibody (6B2) is a mouse monoclonal IgG1 kappa light chain antibody that detects 3PGDH of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). 3PGDH (6B2) antibody is available in a non-conjugated form, providing flexibility for various experimental needs. 3PGDH, consisting of 544 amino acids, plays a crucial role in metabolism and function of the central nervous system, particularly in L-serine and glycine synthesis, which are essential trophic factors supplied by glial cells to support survival and development of central neurons. 3PGDH is expressed in two distinct mRNA transcripts: a dominant 2.1 kb mRNA highly expressed in prostate, testis, ovary, brain, liver, kidney, and pancreas, and a 710 bp mRNA showing high expression in heart and skeletal muscle. Regulation of 3PGDH at transcriptional level is influenced by tissue specificity and cellular proliferative status, highlighting importance in various physiological contexts. A deficiency in 3PGDH can lead to a treatable congenital error that impairs L-serine biosynthesis, resulting in severe neurological consequences such as congenital microcephaly, psychomotor retardation, and seizures, underscoring significance in both developmental biology and potential therapeutic interventions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

3PGDH Antibody (6B2) References:

1. Nucleotide sequence and differential expression of the human 3-phosphoglycerate dehydrogenase gene.  |  Cho, HM., et al. 2000. Gene. 245: 193-201. PMID: 10713460
2. L-serine and glycine serve as major astroglia-derived trophic factors for cerebellar Purkinje neurons.  |  Furuya, S., et al. 2000. Proc Natl Acad Sci U S A. 97: 11528-33. PMID: 11016963
3. 3-phosphoglycerate dehydrogenase deficiency in a patient with West syndrome.  |  Pineda, M., et al. 2000. Dev Med Child Neurol. 42: 629-33. PMID: 11034457
4. Molecular characterization of 3-phosphoglycerate dehydrogenase deficiency--a neurometabolic disorder associated with reduced L-serine biosynthesis.  |  Klomp, LW., et al. 2000. Am J Hum Genet. 67: 1389-99. PMID: 11055895
5. [3-phosphoglycerate dehydrogenase (3PGDH) expression in supporting cells of the rat peripheral nervous system and its upregulation after nerve injury].  |  Yamashita, N. 2002. Hokkaido Igaku Zasshi. 77: 379-87. PMID: 12187834
6. Selective expression of L-serine synthetic enzyme 3PGDH in schwann cells, perineuronal glia, and endoneurial fibroblasts along rat sciatic nerves and its upregulation after crush injury.  |  Yamashita, N., et al. 2003. Arch Histol Cytol. 66: 429-36. PMID: 15018145
7. Crystal structures of type IIIH NAD-dependent D-3-phosphoglycerate dehydrogenase from two thermophiles.  |  Kumar, SM., et al. 2014. Biochem Biophys Res Commun. 451: 126-30. PMID: 25065739
8. Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH).  |  Unterlass, JE., et al. 2017. Oncotarget. 8: 104478-104491. PMID: 29262655
9. 3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment.  |  Li, M., et al. 2021. Cell Oncol (Dordr). 44: 541-556. PMID: 33735398
10. Biochemical and Biophysical Characterization of Recombinant Human 3-Phosphoglycerate Dehydrogenase.  |  Murtas, G., et al. 2021. Int J Mol Sci. 22: PMID: 33921788
11. Identification of Novel Natural Inhibitors to Human 3-Phosphoglycerate Dehydrogenase (PHGDH) for Cancer Treatment.  |  Sadiqa, A., et al. 2022. Molecules. 27: PMID: 36144843
12. Beneficial effects of L-serine and glycine in the management of seizures in 3-phosphoglycerate dehydrogenase deficiency.  |  de Koning, TJ., et al. 1998. Ann Neurol. 44: 261-5. PMID: 9708551

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-3PGDH Antibody (6B2) has 17 citations in a variety of scientific publications.

Primary antibodies like Anti-3PGDH Antibody (6B2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

3PGDH Antibody (6B2) Specifications

Alternate Product Name: 3PGDH

Product Clone Name: 6B2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 1-534

Epitope Target: 3PGDH

Epitope Species: human

Product Reactivity/Detection: 3PGDH

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 100 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 17 citations in various scientific publications

Available Conjugates/Forms for 3PGDH Antibody (6B2): N/A